MXCT MaxCyte, Inc.
$1.16▼ -2.52%
Healthcare
Other
After hours
$1.17▲ +0.84%
Sep 11, 7:36 PM ET
Volume 331.4K
Avg Volume (10D) 476.8K
Key Metrics & Fundamentals
Market Cap
$119.72M
P/E Ratio
–
Div Yield
–%
52W Range
0.64 - 1.87
% vs 50 MA
-6.21%
% vs 200 MA
4.15%
RSI-14
40.7
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.69
Free Cash Flow
-$4.72M
Gross Rev
$7.27M
Gross Profit
$5.60M
EBITDA
-$9.03M
COGS
$1.68M
Operating Exp
$15.83M
Operating Income
-$10.23M
EBIT
-$10.23M
Pretax Income
-$8.87M
Net Income
-$8.87M
EPS (Diluted)
-0.08
Price & Volume History
Loading chart…
Recent News
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 11, 2026 8:30 PM
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 19, 2026 11:01 PM
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
GlobeNewswire · Aug 19, 2026 12:05 PM
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...
GuruFocus.com · Aug 13, 2026 5:03 AM
MaxCyte, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 13, 2026 1:50 AM
MaxCyte Q2 Earnings Call Highlights
MarketBeat · Aug 13, 2026 1:04 AM
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates
Zacks · Aug 12, 2026 10:15 PM
MaxCyte Reports Second Quarter 2026 Financial Results
GlobeNewswire · Aug 12, 2026 8:05 PM
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates
Zacks · Aug 11, 2026 12:20 PM
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Zacks · Aug 5, 2026 12:15 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See MXCT's money flow as a full page
Social Sentiment
No Reddit posts found for MXCT.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.